Cite
Romesser PB, Sherman EJ, Whiting K, et al. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer. 2021;127(22):4161-4170doi: 10.1002/cncr.33804.
Romesser, P. B., Sherman, E. J., Whiting, K., Ho, M. L., Shaha, A. R., Sabra, M. M., Riaz, N., Waldenberg, T. E., Sabol, C. R., Ganly, I., McBride, S. M., Fagin, J. A., Zhang, Z., Tuttle, R. M., Wong, R. J., & Lee, N. Y. (2021). Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer, 127(22), 4161-4170. https://doi.org/10.1002/cncr.33804
Romesser, Paul B, et al. "Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial." Cancer vol. 127,22 (2021): 4161-4170. doi: https://doi.org/10.1002/cncr.33804
Romesser PB, Sherman EJ, Whiting K, Ho ML, Shaha AR, Sabra MM, Riaz N, Waldenberg TE, Sabol CR, Ganly I, McBride SM, Fagin JA, Zhang Z, Tuttle RM, Wong RJ, Lee NY. Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. Cancer. 2021 Nov 15;127(22):4161-4170. doi: 10.1002/cncr.33804. Epub 2021 Jul 22. PMID: 34293201.
Copy
Download .nbib